Falling rupee to usher in double-digit growth for top 20 pharmaceutical companies

After two consecutive years of single-digit expansion, big Indian drug firms are expected to return to double-digit growth in the current fiscal aided by recovery in US sales, weakening of the rupee and revival of domestic demand, ratings agency Crisil said

6-7% – growth in US revenues expected this fiscal

12-13% – growth in domestic revenues of big pharma companies likely this fiscal

7% – revenue from the US market grew in the first quarter

30% – of the revenues are contributed by the US market

35% – of the revenues are drawn from the domestic market

3/4th – of pharma revenues are accounted by top 20 companies

The triggers

• Lower intensity of regulatory issues, faster product approvals and improving share of complex products in the US
• Better access to healthcare and deeper penetration of health insurance in India